
price data provid thomson reuter
number may add due round
initi outperform headach
initi coverag biohaven pharmaceut outperform
price target entranc cgrp antibodi excit
time migrain market potenti arriv oral small molecule-target
cgrp therapi repres anoth step forward rimegep
fda review see attract setup share drug
overal efficacy/safety/formul profil offer altern patient
well receiv addit long-term safeti data every-other-
day prevent dose appear bode well top-lin prevent data
readout model rimegep approv ww total revenu reach
strong catalyst line-up includ six late-stag readout
next month much pipelin captur estim
like potenti upsid beyond target downsid mid-
delay risk/reward appear attract initi outperform
migrain public health issu signific size american migrain
foundat estim patient affect migrain headach
account emerg room visit annual despit rang
approv product exist therapi vari term efficaci toler
profil introduct antibodi target calcitonin gene-rel
peptid cgrp receptor repres excit step forward field
patient anti-cgrp therapi aimovig emgal
teva ajovi collect annual revenu run rate roughli
year post-launch aimovig continu hold lead market share
rimegep product reson inject anti-cgrp agent
also expand number migrain patient treat prevent
therapi howev oral therapi soon reach market
rimegep repres one candid current review
fda pdufa feb drug pharmacokinet profil allow
leverag acut prevent treatment see rimegep
offer best world includ rapid onset action bottom line
see overal profil like reson physician patient model
conserv initi revenu initi year trajectori
observ inject anti-cgrp howev see year gain
traction model revenu reach
launch favorit get catalyst provid off-set
hold roughli six late-stag readout anticip next year
smid-cap biotech commerci launch necessarili well receiv
recent period see consensu expect appear reason
revenu bottom line see downsid downsid
rimegep delay howev addit readout program fulli
captur stock valuat see setup help share work
beyond target
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
biohaven pharmaceut inc clinical-stag biotechnolog compani focus develop novel
therapeut neurolog neurodegen condit lead asset rimegep small molecul
cgrp antagonist current review fda treatment migrain beyond rimegep compani
pipelin span five addit clinic asset nine differ therapeut indic current estim assign
credit rimegep acut treatment prevent migrain numer late-stag
readout plan next month major pipelin effort call option stage combin
dynam differenti product profil rimegep like setup share
rimegep fail reach
market delay via request
addit studi
pipelin effort fail matur
gain
rimegep gain approv
digit share marketplac
rimegep gain approv
migrain surpass
anti-cgrp market share
one indic
gain approv
top-lin phase rimegep data migrain
futil analysi phase troriluzol alzheim
februari regulatori decis oral/odt
rimegep compris largest near-term valu
driver share data unfold
troriluzol becom increasingli import
part stori
target deriv sum-of-part dcf analysi
assign credit potenti cash flow
rimegep discount back
investor sentiment share appear somewhat
mix compani lead asset rimegep
new ct-
headquart clinical-stag biopharma focus
develop novel treatment neurolog
creat bluematrix
tabl content
migrain
prevent vs treatment bright today
migrain landscap cgrp chang treatment landscap
cgrp histori best valid migrain
rimegep readi shake cgrp space
rimegep ounc prevent thought ahead prevent data
walk like duck quack like duck potenti rimegep success prevent
prevent label matter ye brief thought readout
market opportun migrain
valuat deep dive biohaven
minut macro current state biotech sector valuat
tabl figur
figur overview valuat sum-of-part dcf analysi
figur acut treatment option migrain
figur cgrp target strategi migrain
figur cgrp mechan migrain trigger
figur nrx trx count data aimovig ajovi emgal
figur chemic structur rimegep
figur phase rimegep efficaci percent patient pain-fre hour post-dos
figur comparison migrain treatment safeti efficaci
figur summari phase rimegep efficaci assess studi studi
figur chang ham-a score riluzol treatment
figur chang y-boc score riluzol vs placebo
figur chang total modifi sara score troriluzol vs placebo natur
figur comparison acut migrain treatment
figur histor biotech sector valuat price-to-earnings multipl quarter
summari conclus initi coverag biohaven pharmaceut
outperform rate target demarc acut migrain treatment
prevent therapi break introduct cgrp-target therapeut repres
power shift migrain space like first foremost think
oral deliveri rapid onset action well-receiv patient physician
preliminari data suggest benefit prevent acut treatment product
establish differenti versu inject product use acut beyond
rimegep migrain note hold full pipelin help deliv manag
target three market drug current estim assign credit rimegep
leav remaind pipelin call option fulli acknowledg
biotech commerci launch faint heart face formid
competit establish player see rimegep differenti asset bottom
line share trade near valuat four phase studi underway
multipl valu lever pull work share beyond target element
thesi follow
one size fit migrain
us patient affect migrain repres signific public health problem
introduct therapi target calcitonin gene-rel peptid cgrp receptor
repres meaning chang prevent treatment migrain date three
cgrp monoclon antibodi approv aimovig ajovi emgal
prepar advanc rimegep oral small molecul cgrp antagonist nda
current review one oral tablet one rapidli dissolv tablet pdufa
rimegep hold potenti first oral cgrp therapi reach market
rimegep prevent studi set read assum success
prevent acut treatment market launch model revenu reach
rimegep current command spotlight compani pipelin
incorpor numer phase program underway next-gener cgrp candid
vazegep intranasally-deliv formul phase studi
top-lin data anticip complement cgrp franchis also advanc
troriluzol seri relat indic includ alzheim diseas
gener anxieti disord current estim assign credit
migrain total revenu reach leav remaind pipelin
asset call option base share current trade see littl credit assign
effort see interest setup success manifest one
like combin de-risk opportun broad pipelin attract
base review rimegep data ascrib high probabl success
remain rimegep phase prevent readout admittedli see acut market
contribut valuat prevent opportun per share prevent
acut treatment step back consid risk/reward see downsid high-
rimegep prevent effort delay howev upsid target
achiev introduct troriluzol effort and/or lower
discount rate commerci launch admittedli faint heart
face steep competit establish large-cap player said even
current rimegep estim initi launch year fall report revenu
product like aimovig emgal vs get target
bottom line see rimegep product profil offer differenti product
substanti portion market still find treatment offer relief see
attract opportun disrupt initi coverag outperform rate target
figur illustr current develop pipelin novemb
note advanc pipelin effort focu primarili upon rimegep oral small
molecul inhibitor calcitonin gene-rel peptid cgrp receptor present two
rimegep new drug applic nda review approv fda cover two
differ formul tablet zydi rapidli dissolv base recent manag
commentari believ zydi singl formul commerci
instead tablet formul addit rimegep also hold third-gener
cgrp receptor antagonist known vazegep phase develop
use intranas deliveri format differ chemic entiti compar rimegep
would intend use immedi rescu therapi product look beyond cgrp
antagon pipelin
includ addit asset target glutam
myeloperoxidas mpo system see figur
tabl summar relev catalysts/data mileston relev bhvn
develop strategi deem like potenti impact share
impact near term potenti approv lead asset rimegep
treatment prevent migrain addit current four differ
phase studi underway glutam modul mpo inhibitor program see figur
studi troriluzol alzheim diseas anticip futil
analysi also like relev mileston see
describ detail herein deriv price target share primarili
use sum-of-part dcf analysi valuat methodolog examin cash
flow gener per-product basi rimegep next-gen cgrp
vazegep complement primari analysi also examin potenti fair valu
use compar multipl valuat approach price-to-earnings p/ put initi result
context howev import note believ sum-of-part dcf strategi repres
rigor approach development-stag and/or earli commercial-stag biotech
limit earn histori commerci experi
tabl illustr overal valuat contribut specif program well
bhvn current net cash pro forma basi follow compani june secondari
offer incorpor one addit financ pleas see pp
comprehens descript valuat risk/reward analysi
figur overview valuat sum-of-part dcf analysi
migrain
headach account roughli admiss hospit emerg room
epidemiolog studi suggest popul affect headach
least one point life look specif chronic migrain term
evolv year howev criteria formal intern classif
headach disord diagnost criteria featur includ follow
frequenc least five attack fulfil criteria
characterist least two follow
aggrav caus avoid physic activ walk climb
during-headach symptom least one follow
photophobia phonophobia
explain anoth diagnosi
prevent vs treatment bright today
migrain therapeut landscap seen introduct cgrp-target therapi
physician patient treat migrain undergon shift figur
illustr histor demarc follow prevent acut treatment
migrain patient acut attack elig treatment prevent also
appropri patient experienc frequent episod within cgrp space
approv antibodi fall domain bhvn rimegep abbv/agn ubrogep
two small molecul cgrp modul also evalu prevent therapi
see
current state acut treatment
beyond over-the-count over-the-counter treatment nsaid triptan class repres one
mainstay treatment acut segment figur summar rang treatment
option current consid patient experienc acut migrain episod
figur acut treatment option migrain
current state prevent treatment
patient experi frequent headach disrupt everyday activ
work school consid candid prevent treatment reduc number
migrain day experi nearli one year ago american headach societi releas
posit statement offer guidelin physician integr newer
agent treatment posit statement specif highlight new
anti-cgrp treatment well botox approv prevent treatment
migrain adult addit agent soon reach market rimegep
lasmiditan anticip continu evolut treatment guidelin notabl present
though cgrp-target therapi thought potenti without need
migrain landscap cgrp chang treatment landscap
cgrp histori best valid migrain
studi demonstr role calcitonin-rel gene peptid cgrp
receptor pain signal specif role migrain pain therapeut modul first
describ sinc time gepant class expand
first anti-cgrp gain approv fda aimovig erenumab figur shown
depict mechan work antibodi teva target peptid
aimovig block receptor complex
figur cgrp target strategi migrain
cgrp make uniqu target migrain discuss cgrp neurologist
dr david dodick describ peptid best valid target migrain
work lar edvinsson colleagu demonstr elev cgrp level blood
patient experienc migrain studi report lassen
intraven infus cgrp result initi migrain subject
placebo patient one eleven subject report headach shown figur
cgrp act vasodil pain-sign neurotransmitt within brain
trigemin nerv releas cgrp thought involv pain signal within face
head jaw
figur cgrp mechan migrain trigger
figur illustr current breakdown prescrib pattern cgrp-target
therapi shown amgn aimovig continu hold lead term count
roughli share lli emgal antibodi bind cgrp peptid current
compris approxim share space remain share ascrib
teva ajovi aimovig first product reach market three
figur nrx trx count data aimovig ajovi emgal
figur shown illustr current report revenu variou anti-cgrp
therapi launch financi report amgn aimovig first launch
ajovi emgal arriv septemb three drug
combin report revenu see figur
rimegep readi shake cgrp space
rimegep origin discov scientist bristol-my
squibb bm medicin chemistri optim campaign sought develop small-
molecul cgrp receptor figur shown illustr chemic
structur rimegep preclin studi rimegep demonstr favor oral
bioavail rodent non-human primat anim model along sub-nanomolar
inhibit ki cgrp receptor
figur chemic structur rimegep
bm conduct phase dose-rang studi rimegep examin efficaci
acut treatment migrain use four key efficaci measur pain resolut nausea
photophobia figur illustr overal design studi
evalu multipl dose rimegep activ control
sumatriptan placebo
primari endpoint studi examin proport patient achiev pain-fre
statu two hour post-dos rimegep dose yield biggest
increas respect compar among placebo-tr
subject higher rimegep dose yield increment efficaci benefit see figur
howev bm termin program part due respons seen versu activ
compar sumatriptan achiev rate patient pain-fre two hour
addit two patient experienc liver enzym elev one cohort
placebo group
figur phase rimegep efficaci percent patient pain-fre hour post-dos
drew opportun efficaci versu sumatriptan concern
look prior public describ sumatriptan respons rate report valu
studi appear somewhat better-than-norm prior studi second studi
power show statist comparison sumatriptan rimegep final
rimegep result contrast versu agent note similar level
efficaci figur highlight compar number agent near potenti
approv market extend fact rimegep
oral administ either tablet rapidli dissolv tablet offer conveni
figur comparison migrain treatment safeti efficaci
note respons defin mild pain pain free hour includ patient may receiv
second dose hour ubrogep dose reach signific mb endpoint ae data
phase studi dose incorpor
beyond aspect point drug potenc oral deliveri format efficaci across
multipl efficaci measur low risk cardiovascular side effect sinc acquir asset
conduct extens develop plan incorpor addit phase safeti
studi two phase studi acut treatment prevent phase migrain studi
long-term safeti studi examin highlight report give better
understand drug safeti efficaci profil
manag indic focu market effort primarili zydi
formul strateg perspect think make sens simplifi
messag tilt toward agent robust data provid brief review
data deriv studi oral tablet formul
two studi evalu oral rimegep formul studi met
primari endpoint combin pain freedom freedom
bothersom symptom two hour tabl demonstr rimegep also
demonstr signific improv across rang measur includ assess
durabl respons hour later hour later
figur summari phase rimegep efficaci assess studi studi
nausea freedom two hour post-dos significantli differ rimegep
show improv time appear durabl hour see figur
rimegep formul offer rapidli dissolv format patient also
evalu phase studi versu placebo manag indic formul
repres sole formul pursu commerci shown figur studi
met co-primari endpoint also demonstr statist
signific improv nausea hour post dose maintain hour
see figur
pain nausea repres key symptom patient seek resolv migrain
attack rimegep also appear demonstr rapid onset pain relief phase
studi show separ versu placebo within first hour focus
rigor assess pain freedom pain note rimegep demonstr
signific improv versu placebo minut follow dose see figur
note pain freedom defin patient pain specifi interv estim comput
use modifi intent-to-treat popul cmh method subject use rescu medic
assess classifi failur
see find particularli relev compar competitor urbogep profil
figur illustr placebo-adjust differ censor data appear show
somewhat lower degre benefit versu rimegep cross-trial comparison inher
limit caveat extrapol bottom line think rimegep appear well
bottom line see overal phase result report date offer competit product
profil versu exist agent market formul offer better efficaci
profil rapid onset activ rel unev safeti profil particularli contrast
triptan drug class anticonvuls think rimegep stack
favor marketplac furthermor anti-cgrp compani alreadi much
heavi lift term patient prescrib educ mechan action
make market case somewhat easier deliv
rimegep ounc prevent thought ahead prevent
beyond pivot studi acut treatment also explor potenti
rimegep acut treatment episod migrain earlier phase rimegep data
suggest drug longer half-lif may offer opportun sustain effect
anti-cgrp candid gain approv prevent therapi advanc rimegep
pivot prevent studi phase prevent studi assess chang baselin
mean number migrain day per month cours three-month treatment period
week subject random receiv either rimegep everi day
week placebo studi includ extens period figur
illustr studi design
walk like duck quack like duck potenti rimegep success prevent
potenti readout rimegep prevent studi examin
potenti success event simpli put scientif rational appear strong view
rimegep use prevent treatment prior studi demonstr cgrp
increas migrain anti-cgrp therapi offer prevent thu risk due
mechanist failur rimegep seem unlik demonstr drug
bioavail reach target appropri time window
clinic rimegep data also suggest role rimegep prevent
prior rimegep acut treatment clinic data offer direct support potenti
prevent indic figur shown come phase long-term studi
rimegep placebo-control set think data
support recal studi explor rimegep dose everi day qod prn
need subject studi migrain day per month qod prn arm
track durat trial determin impact migrain frequenc
shown subject experienc declin day per month month studi
pivot studi emgal note reduct similar absolut magnitud month
roughli day aimovig demonstr reduct day month also
report respons rate reduct migrain monthli day somewhat
difficult contextu without placebo control result compris smaller
number lack placebo control think qod dose yield least similar result
aimovig emgal reduct monthli migrain day
long-term safeti studi provid potenti insight on-going prevent studi
look first toler profil figur summar advers event report
rimegep long-term studi purpos compar prevent studi see
qod prn arm relev studi placebo control patient
howev note discontinu rate due ae report rel
arm studi ae incid rate percentag basi appear lower type event
see figur also import report alt/ast elev uln bilirubin
elev given focu safeti would appear import rimegep
note prn dose need migrain days/mo baselin prn dose need
migrain days/mo schedul qod prn rimegep everi day supplement need
prevent label matter ye brief thought readout
introduct anti-cgrp therapi marketplac chang manner
physician approach prevent acut migrain treatment complet label
encompass mode treatment prefer even patient take drug
tabl shown summar outcom migrain prevent therapi give
perspect necessari demonstr rimegep set
perhap relev comparison metric focu chang baselin
number headach day per month focus placebo-adjust valu note
aimovig erenumab emgal galcanezumab appear show greatest benefit
label indic day reduct frequenc headach day versu placebo
proport patient fewer monthli migrain day agent rang
aimovig depend dose emgal dose
toler profil differ agent compar rimegep botox requir multipl
inject everi week aimovig emgal
discontinu rate inject low singl digit rate although topiram
also use prevent agent show somewhat similar efficaci toler profil
stand higher discontinu rate due paresthesia nausea fatigu
beyond rimegep also advanc troriluzol multipl phase studi rang
neurolog disord see figur troriluzol repres peptid prodrug
approv therapi rilutek riluzol acquir via al biopharma chase chemic
divers center fccdc although estim current assign credit troriluzol
review compound program sever key readout draw closer
troriluzol glutam transport modul thought increas activ
excitatori amino-acid transport eatt increas glutam clearanc troriluzol
first evalu phase studi normal healthi volunt dose-rang studi
examin singl multipl dose daili notabl compar
riluzol troriluzol appear greater system exposur activ metabolit
extend tmax increas bioavail vs follow subsect
describ detail advanc troriluzol program underway
weve seen far
review potenti upcom troriluzol readout one first
anticip phase top-lin result studi troriluzol gad estim primari
complet date riluzol previous examin open-label studi gad
studi examin effect riluzol per day week
subject complet studi two discontinu due advers event focus ham-a
score chang examin troriluzol note riluzol reduc
ham-a score week
figur chang ham-a score riluzol treatment
note signific differ baselin
riluzol gad data compris small patient number open-label studi
howev see sever encourag signal relat troriluzol first advers event
limit studi two discontinu due dizziness/nausea cognit
slow creat opportun troriluzol differenti sign liver toxic
studi note research indic also one reason higher dose
explor second efficaci appear least consist result observ
agent ham-a score chang basi pro-drug format offer consist
respons avoid safeti liabil associ riluzol would seem
posit outcom gad market within us larg affect gad one point
life estim roughli one-third case consid sever point
incorpor troriluzol credit gad market await clariti phase
riluzol previous examin adjunct treatment ocd patient current
take look closer result ocd studi allow concomit
treatment employ studi prior riluzol studi examin fluvoxamin plu
riluzol versu fluvoxamin alon subject enrol cohort primari
endpoint chang y-boc total score baselin time figur illustr
chang y-boc total score week total y-boc score significantli differ
treatment effect point
figur chang y-boc score riluzol vs placebo
note dark circl fluvoxamin placebo gray triangl fluvoxamin riluzol
list report advers event riluzol ocd studi combin
fluvoxamin note overal limit number report studi incorpor
smaller design report diarrhea one case liver function abnorm stand
riluzole-tr arm
result mean ocd indic novel agent
approv specif ocd remain meaning unmet need popul bottom
line see indic one particularli challeng step back examin
prior adjunct treatment result riluzol see concomit mediat issu
like serv confound studi howev one difficult mitig
troriluzol offer improv bioavail toler could benefici
prior studi demonstr glutam transport express decreas cortex
ad preclin studi riluzol demonstr administr drug
rescu cognit deficit y-maze water maze compar anim overexpress tau
taken togeth result would suggest potenti role riluzol potenti
therapeut applic ad patient
conduct futil analysi troriluzol phase ad studi protect ad
first subject reach week treatment phase see trial design figur overal
studi enrol approxim subject random once-daili
troriluzol arm placebo shown
studi continu progress toward conclus assum one two outcom
achiev first subject
improv adas-cog endpoint differ
demonstr improv volumetr mri
declin volumetr mri show shrink tempor lobe time volumetr mri
yet standard diagnos ad part hippocamp atrophi link normal
age-rel declin one recent studi publish group research univers
describ new structur model help guid ad brain may diverg
cognit normal brain time manag guid specif degre benefit
seek detect interim analysi howev note clinic trial
incorpor volumetr mri thought outperform trial reli sole cognit
initi examin troriluzol phase studi compar troriluzol dose
versu placebo week octob compani announc studi fail meet
primari endpoint chang sara score week troriluzol placebo show
meaning differ vs addit improv
secondari endpoint patient global impress chang across troriluzol placebo
vs perhap notabl absenc meaning safeti event
report clinic signific effect liver function recal limit associ
manag note placebo respons studi appear higher prior
studi riluzol addit shown figur result
extens phase studi demonstr improv modifi version
sara scale obtain definit guidanc fda use measur
examin long-term result see continu improv time beyond week
figur chang total modifi sara score troriluzol vs placebo natur
figur illustr data subject phase studi troriluzol sca
shown figur troriluzole-tr subject show improv point
sara score week treatment troriluzol compar natur histori data
caveat type comparison limit particularli contrast versu
direct placebo control group encourag direction chang seen
data see point chang sara score repres clinic meaning chang
thu replic versu placebo-control group think would repres
initi phase sca studi troriluzol per clinicaltri gov
primari complet date studi project octob thu top-lin phase data
roughli one year away current studi incorpor higher troriluzol dose versu
prior studi qd vs qd addit studi enrich sca type
repres popul faster diseas progress final modifi sara
score incorpor gait stanc sit speech disturb versu full score
incorpor addit fine motor assess difficult ascertain
chang impact overal outcom encourag gotten fda support
modifi sara scale implement
assign credit opportun estim note orphan market
estim sca patient us mani orphan indic command
elev price believ would necessarili case troriluzol given
explor util rang larger opportun although sca market may
smaller one revenu basi orphan drug design deliv regulatori exclus
could meaning life cycl manag perspect
market opportun migrain
follow section describ detail current market model rimegep
migrain prevention/episod market although phase studi troriluzol
underway multipl indic leav effort unmodel estim
figur illustr market model rimegep us migrain prevent
market base data variou compani american migrain
foundat estim approxim us migrain patient migrain
experienc patient vari term presentation/symptom sever
frequenc estim roughli one-third patient patient experi
chronic migrain make elig candid prevent therapi within group
assum approxim one-third current seek prevent treatment roughli
patient annual see figur
continu guid phase top-lin data rimegep migrain prevent
present assum gain approv first treatment indic base
current submiss subsequ snda file rimegep prevent
indic thu assum initi revenu deriv prevent market first
manifest approxim one year launch acut treatment set
current inject anti-cgrp therapi price per patient per year launch
assum modest list price per year rimegep
equival price assumpt across two differ formul appli discount
complianc factor deriv net price per year per patient see figur
submit nda rimegep util prioriti review voucher prv
result six-month review period rimegep submission/accept
occur latest indic advisori committe meet
necessari impli pdufa date rimegep thu assum initi us
commerci launch commenc later figur illustr current
assumpt acut treatment market within us
assum equival price across rimegep oral formul acut
treatment model focus migrain patient chronic natur
experienc prior prevent treatment failur accord martelletti
estim constitut roughli market patient take
prescript therapi yield potenti acut treatment market patient
anticip overli broad warn restrict would prevent usag narrow
market acut treatment revenu estim reach
figur describ acut rimegep price model price per pill basi
assum pariti across formul assum averag migrain
per month chronic segment market translat per year
annual list basi per year net basi see figur
key question remain unansw near term rimegep may
posit commerci marketplac current launch environ
backdrop larger player differenti profil critic success
end figur contrast key attribut associ rimegep versu
categori acut migrain treatment context migrain patient
focus resolut symptom rapid manner see rimegep well
posit versu newer agent lli lasmiditan abbv/agn ubrogep
improv oral triptan also import
figur comparison acut migrain treatment
valuat deep dive biohaven
minut macro current state biotech sector valuat
tabl summar current valuat metric large-cap mid-cap commerci
stage biotechnolog compani see relev peer group mid-cap
commerci group highlight mid-cap commerci peer group current trade
mean consensu revenu median
note price
compar histor basi figur attempt put tempor context
around current sector-level valuat histor sinc large-cap peer group
figur histor biotech sector valuat price-to-earnings multipl quarter
rel biotech peer group histor trade premium multipl
howev note sinc large-cap biotech peer group begun trade
discount broader market
figur illustr recent trade histori share event
impact share either posit neg recal although compani found
late complet ipo thu compani overal trade
histori somewhat condens
histor inflect point share larg coincid data result strateg
announc competit updat look ahead near term see multipl
data readout continu repres key driver share given compani stage
develop describ detail base case valuat scenario well
potenti sourc upsid downsid relat
beyond primari valuat analysi also examin altern valuat
methodolog triangul current price target note approach
also sensit select discount rate multipl valuat year figur
illustr potenti fair valu estim use respect approach
compar primari target deriv via sum-of-part dcf analysi
select valuat year p/ price-to-earnings analys see prior figur
like repres steady-st period revenu growth compar potenti
period rimegep launch phase addit adher discount rate
also consist rate use primari valuat methodolog appropri
likewis current mean peer revenu multipl rang consensu revenu
mid-cap large-cap group p/ valuat analysi select revenu
multipl discount current mid-cap peer group given bhvn develop
stage profil view like eventu peer group discount
futur mid-cap commerci peer appear warrant given fact compani still
pre-commerci stage develop price-to-earnings valuat analysi earn multipl
also discount large-cap peer current lack consist posit earn
histori valuat obtain via price-to-earnings p/ analysi appear somewhat lower
sum-of-part fair valu estim vs note sum-of-part valuat
incorpor net cash per share valuat thu believ three approach
yield similar targets/fair valu estim share
share current trade rang share
outperform nasdaq biotechnolog index former return ytd vs
nbi backdrop number near-term catalyst examin
potenti risk/reward setup share depict figur see risk/reward
skew upsid share
note price
current base case scenario target impli upsid rel share current
trade term potenti downsid delay regulatori review time market
logic issu could impact share use exampl push
potenti commerci launch two year repres neg impact fair
valu estim fall rimegep acut treatment studi complet
publish see larg de-risk opportun stage forthcom
prevent readout would seem high likelihood success base prior data
space howev readout neg impos lengthi delay year complet
remov fair valu estim lower target per share put
thing togeth estim share could reach setback see
downsid scenario share clear hold posit bia forthcom
prevent readout see unlik scenario
anoth bear case share rimegep face commerci challeng
posit versu newer product larg player well gener
agent triptan key question address whether gain traction marketplac
although current rimegep estim assum drug reach singl digit share
migrain prevent treatment market reduct rimegep estim
lower price target reduct per share
base case assum target see potenti upsid beyond level
multipl lever one exampl realiz via lower discount rate current
valuat appli discount rate reflect compani current stage develop
pre-commerci execut commerci market demonstr traction
rimegep marketplac could see case made lower rate
would yield target
anoth logic sourc upsid realiz incorpor addit pipelin
opportun present base case assum success rimegep migrain
prevent acut treatment market migrain treatment
multipl phase program develop sever readout approach
beyond end achiev clinic success one effort
see upsid current valuat
histor mid-cap biotech commerci launch often daunt prospect compani
get infrastructur place commenc sale market effort rimegep launch
mark first effort note rel cgrp launch
aimovig emgal ajovi rimegep estim fall toward low end report
revenu see figur first four quarter launch report aimovig
total revenu report total emgal revenu current
rimegep revenu first four quarter current total
rimegep launch curv follow closer trajectori emgal would repres
near doubl current estim adjust revenu trajectori acut treatment
market accordingli would yield increas target fair valu
biohaven pharmaceut new ct-base late-stag clinic biopharma
focus discov develop market novel therapi neurolog
neuropsychiatr condit found focus combin intern
develop effort in-licens asset advanc multipl program compani
initi effort center acquir glutam platform univers yale
complement activ secur right bmss rimegep bhv-
astrazeneca compani current pipelin encompass program plu
overal bhvn current manag team hold extens experi discoveri
develop market biopharma product member execut team
describ
dr coric found biohaven pharmaceut serv compani ceo prior
found biohaven dr coric held role academia industri includ yale
univers bristol-my squibb yale dr coric serv chief yale clinic
neurosci research time bristol-my squibb dr coric involv
numer clinic develop effort includ abilifi opdivo yervoy daklinza
continu serv associ clinic professor psychiatri yale school medicin
dr coric obtain md wake forest univers school medicin north carolina
mr engelhart current serv cfo held role sinc join compani
may prior join execut team mr engelhart execut director
alexion pharmaceut previous held financi leadership role bristol-my
squibb schering-plough mr engelhart earn bs villanova univers
dr stock join team compani chief portfolio strategi
develop august promot current role
respons clinic develop dr stock previous bristol-my squibb
year involv develop abilifi orenc emplic dr stack obtain
md new york univers school medicin
dr conway appoint current role cso prior join dr
conway led bristol-my squibb biolog program identifi novel cgrp receptor
antagonist includ rimegep dr conway earn phd neurosci
univers california santa barbara
mr jone current serv compani chief commerci offic prior appoint
current posit mr jone held commerci leadership role takeda pharmaceut
bristol-my squibb boehringer-ingelheim nitrom astrazeneca mr jone obtain
bs academi ms texa stanford graduat
school busi addit time industri mr jone serv
weatheral diagnosi treatment chronic migrain therapeut
advanc chronic diseas pp
tepper histori review anti-calcitonin gene-rel peptid cgrp
therapi translat research treatment headach suppl
fda approv first drug prevent migrain here stori discoveri
limit scienc aaa
may caus role migrain cephalalgia
 lentz mercer et al discoveri potent oral activ
human cgrp receptor antagonist treatment migrain ac chem lett
santon schartman et al discoveri
gene-rel peptid cgrp antagonist clinic trial treat migrain
 goadsbi dodick stock mano fischer
acut treatment migrain double-blind random placebo control
 michelson phase iib random double-blind placebo-control trial
ubrogep acut treatment migrain cephalalgia
studi group behalf lasmiditan effect acut treatment
lipton efficaci safeti toler rimegep oral disintegr tablet
acut treatment migrain randomis phase double-blind placebo-
conway coric goadsbi rimegep oral calcitonin gene-rel
peptid receptor antagonist migrain engl
stauffer dodick zhang ailani conley evalu
galcanezumab prevent episod migrain random
 phase random placebo-control double-blind studi lasmiditan acut
treatment migrain brain
open-label trial riluzol gener anxieti disord psychiatri
mohammadinejad zeinoddini akhondzadeh riluzol augment
fluvoxamin moder sever obsessivecompuls disord random
glutam water channel protein tempor
cortex alzheim diseas neuropathol neurobiol
 manjn lanuza cathelin lifespan chang human brain
ferraldeschi vulpiani ponzelli et al riluzol patient hereditari
vanacor salvetti riluzol cerebellar ataxia random double-blind
survey global studi diseas burden among individu migrain
incom statement
good sold
non-cash int exp mandatorili redeem pref share
non-cash interest expens liabiltiy relat sale futur royalti
chang fair valu warrant liabil
chang fair valu deriv liabil
chang fair valu conting equiti liabil
loss equiti method invest
provis incom tax
net loss attribut non-control interest
accret benefici convers featur
 expens revenu
sg expens revenu
target deriv sum-of-part dcf analysi assign credit potenti cash flow rimegep
discount back
risk attain price rate
clinic data emerg clinic studi significantli impact share either posit neg direct
regulatori biohaven may employ acceler strategi gain approv also seek use registr
pathway regul may requir addit data could alter requir approv necessit addit longer
studi failur gain product label lack certain featur could limit biohaven abil gain traction market
commerci failur execut commerci inabl meet/exce expect impact share
competit updat competitor may posit neg impact share relev competitor includ compani
lilli teva gener compani competitor like emerg time
laura chico certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view contain
report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
novemb
novemb
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
